Cargando…
Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment
PURPOSE: Hepatocellular carcinoma (HCC) patients usually achieve a complete response after treatment. This study was aimed to assess the clinical outcome of HCC patients who had achieved a complete response but later presented with elevated tumor marker levels without an identifiable recurrent tumor...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794219/ https://www.ncbi.nlm.nih.gov/pubmed/35085305 http://dx.doi.org/10.1371/journal.pone.0262750 |
_version_ | 1784640785233215488 |
---|---|
author | Kim, Ka Eun Sinn, Dong Hyun Choi, Moon Seok Kim, Honsoul |
author_facet | Kim, Ka Eun Sinn, Dong Hyun Choi, Moon Seok Kim, Honsoul |
author_sort | Kim, Ka Eun |
collection | PubMed |
description | PURPOSE: Hepatocellular carcinoma (HCC) patients usually achieve a complete response after treatment. This study was aimed to assess the clinical outcome of HCC patients who had achieved a complete response but later presented with elevated tumor marker levels without an identifiable recurrent tumor on gadoxetic acid-enhanced magnetic resonance imaging (MRI). METHODS: We retrospectively reviewed the clinical outcome of 58 HCC treated patients who had achieved a complete response but later was referred to our institution’s multidisciplinary tumor board for a clinically suspected hidden HCC recurrence based on elevated tumor marker levels but negative gadoxetic acid-enhanced MRI. The imaging studies, tumor markers, and clinical information were reviewed. The total follow-up period was at least 15 months after the initial negative gadoxetic acid-enhanced MRI. RESULTS: Follow-up imaging studies detected an HCC lesion in 89.7% (n = 52/58) of the patients within the study period, and approximately half of the tumors (46.2%, n = 24/52) developed within 3 months. The most frequent site of recurrence was the liver (86.5%; n = 45/52), but extra-hepatic metastasis was also common (19.2%; n = 10/52). In 5.8% (n = 3/52), HCC reoccurred in the combined form of intra-hepatic and extra-hepatic recurrence. Extra-hepatic metastasis alone occurred in 13.5% (n = 7/52) of patients. CONCLUSIONS: HCC frequently recurred within a short interval in patients who achieved a complete response to treatment in the presence of increased tumor marker levels, even if gadoxetic acid-enhanced MRI was negative. Under such circumstances, we suggest a short-term follow-up including, but not limited to, gadoxetic acid-enhanced MRI along with systemic evaluation. |
format | Online Article Text |
id | pubmed-8794219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87942192022-01-28 Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment Kim, Ka Eun Sinn, Dong Hyun Choi, Moon Seok Kim, Honsoul PLoS One Research Article PURPOSE: Hepatocellular carcinoma (HCC) patients usually achieve a complete response after treatment. This study was aimed to assess the clinical outcome of HCC patients who had achieved a complete response but later presented with elevated tumor marker levels without an identifiable recurrent tumor on gadoxetic acid-enhanced magnetic resonance imaging (MRI). METHODS: We retrospectively reviewed the clinical outcome of 58 HCC treated patients who had achieved a complete response but later was referred to our institution’s multidisciplinary tumor board for a clinically suspected hidden HCC recurrence based on elevated tumor marker levels but negative gadoxetic acid-enhanced MRI. The imaging studies, tumor markers, and clinical information were reviewed. The total follow-up period was at least 15 months after the initial negative gadoxetic acid-enhanced MRI. RESULTS: Follow-up imaging studies detected an HCC lesion in 89.7% (n = 52/58) of the patients within the study period, and approximately half of the tumors (46.2%, n = 24/52) developed within 3 months. The most frequent site of recurrence was the liver (86.5%; n = 45/52), but extra-hepatic metastasis was also common (19.2%; n = 10/52). In 5.8% (n = 3/52), HCC reoccurred in the combined form of intra-hepatic and extra-hepatic recurrence. Extra-hepatic metastasis alone occurred in 13.5% (n = 7/52) of patients. CONCLUSIONS: HCC frequently recurred within a short interval in patients who achieved a complete response to treatment in the presence of increased tumor marker levels, even if gadoxetic acid-enhanced MRI was negative. Under such circumstances, we suggest a short-term follow-up including, but not limited to, gadoxetic acid-enhanced MRI along with systemic evaluation. Public Library of Science 2022-01-27 /pmc/articles/PMC8794219/ /pubmed/35085305 http://dx.doi.org/10.1371/journal.pone.0262750 Text en © 2022 Kim et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kim, Ka Eun Sinn, Dong Hyun Choi, Moon Seok Kim, Honsoul Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment |
title | Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment |
title_full | Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment |
title_fullStr | Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment |
title_full_unstemmed | Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment |
title_short | Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment |
title_sort | outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver mri after a complete response to hepatocellular carcinoma treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794219/ https://www.ncbi.nlm.nih.gov/pubmed/35085305 http://dx.doi.org/10.1371/journal.pone.0262750 |
work_keys_str_mv | AT kimkaeun outcomesofpatientspresentingwithelevatedtumormarkerlevelsbutnegativegadoxeticacidenhancedlivermriafteracompleteresponsetohepatocellularcarcinomatreatment AT sinndonghyun outcomesofpatientspresentingwithelevatedtumormarkerlevelsbutnegativegadoxeticacidenhancedlivermriafteracompleteresponsetohepatocellularcarcinomatreatment AT choimoonseok outcomesofpatientspresentingwithelevatedtumormarkerlevelsbutnegativegadoxeticacidenhancedlivermriafteracompleteresponsetohepatocellularcarcinomatreatment AT kimhonsoul outcomesofpatientspresentingwithelevatedtumormarkerlevelsbutnegativegadoxeticacidenhancedlivermriafteracompleteresponsetohepatocellularcarcinomatreatment |